Literature DB >> 8306343

Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas.

C Cordon-Cardo1, E Latres, M Drobnjak, M R Oliva, D Pollack, J M Woodruff, V Marechal, J Chen, M F Brennan, A J Levine.   

Abstract

Genetic alterations in the p53 and mdm2 genes have been reported to occur in soft tissue sarcomas. This study was designed to determine the prevalence and potential clinical value of detected molecular abnormalities and altered patterns of expression of mdm2 and p53 genes in adult soft tissue sarcomas. A cohort of 211 soft tissue sarcomas from adults that were both clinically and pathologically well characterized was analyzed. Monoclonal antibodies directed against mdm2 and p53 proteins were used to measure overexpression of these proteins in the nuclei of cells from sections of these tumors. Seventy-six of 207 tumors had abnormally high levels of mdm2 proteins and 56 of 211 tumors overexpressed p53 protein. Twenty-two cases had abnormally high levels of both mdm2 and p53 proteins based upon immunoreactivity with these antibodies. There was a striking statistically significant correlation between the overexpression of p53 and mdm2 proteins in the same tumor and poor survival (P < 0.05) of the patients. A group of 73 soft tissue sarcomas was chosen for analysis using Southern blots, single strand conformation polymorphisms, and direct DNA sequencing to confirm mdm2 gene amplifications and p53 mutations and correlate these with the results of the immunoreactivities. The overexpression of p53 and mdm2 proteins in the nuclei of tumor cells did not always correlate well with gene amplification at the mdm2 locus or mutation at the p53 gene. The possible reasons for these discrepancies are discussed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8306343

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  131 in total

Review 1.  Soft tissue sarcomas and p53 mutations.

Authors:  H Taubert; A Meye; P Würl
Journal:  Mol Med       Date:  1998-06       Impact factor: 6.354

Review 2.  Mdm2: the ups and downs.

Authors:  T Juven-Gershon; M Oren
Journal:  Mol Med       Date:  1999-02       Impact factor: 6.354

3.  MDM2 suppresses p73 function without promoting p73 degradation.

Authors:  X Zeng; L Chen; C A Jost; R Maya; D Keller; X Wang; W G Kaelin; M Oren; J Chen; H Lu
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

Review 4.  Modeling sarcomagenesis using multipotent mesenchymal stem cells.

Authors:  Rene Rodriguez; Ruth Rubio; Pablo Menendez
Journal:  Cell Res       Date:  2011-09-20       Impact factor: 25.617

5.  A genetic approach to mapping the p53 binding site in the MDM2 protein.

Authors:  D A Freedman; C B Epstein; J C Roth; A J Levine
Journal:  Mol Med       Date:  1997-04       Impact factor: 6.354

6.  Deletion of RB exons 24 and 25 causes low-penetrance retinoblastoma.

Authors:  R Bremner; D C Du; M J Connolly-Wilson; P Bridge; K F Ahmad; H Mostachfi; D Rushlow; J M Dunn; B L Gallie
Journal:  Am J Hum Genet       Date:  1997-09       Impact factor: 11.025

7.  SCFFBXO22 targets HDM2 for degradation and modulates breast cancer cell invasion and metastasis.

Authors:  Jin Bai; Kenneth Wu; Meng-Han Cao; Yingying Yang; Yu Pan; Hui Liu; Yizhou He; Yoko Itahana; Lan Huang; Jun-Nian Zheng; Zhen-Qiang Pan
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-28       Impact factor: 11.205

Review 8.  Posttranscriptional regulation of p53 and its targets by RNA-binding proteins.

Authors:  Jin Zhang; Xinbin Chen
Journal:  Curr Mol Med       Date:  2008-12       Impact factor: 2.222

9.  p18Ink4c and p53 Act as tumor suppressors in cyclin D1-driven primitive neuroectodermal tumor.

Authors:  Raya Saab; Carlos Rodriguez-Galindo; Kelly Matmati; Jerold E Rehg; Shannon H Baumer; Joseph D Khoury; Catherine Billups; Geoffrey Neale; Kathleen J Helton; Stephen X Skapek
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

Review 10.  MdmX regulates transformation and chromosomal stability in p53-deficient cells.

Authors:  Zdenka Matijasevic; Anna Krzywicka-Racka; Greenfield Sluder; Stephen N Jones
Journal:  Cell Cycle       Date:  2008-10-15       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.